Advertisement
Advertisement
-
Money /

Markets & Investing

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

US investors increase buying of Hong Kong, mainland Chinese stocks

American investors bought US$15 billion of Hong Kong and mainland stocks in 2025, as buying picked up steam through the year.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW